Nuvectra Reports Fourth Quarter and Full Year 2017 Financial Results

Nuvectra (NASDAQ:NVTR), a neurostimulation medical device company, announced financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

Scott Drees, CEO, said, “In 2017, our first full commercial year, we demonstrated our ability to compete in the SCS market, delivering over $10 million in Q4 Algovita revenue. As we move into 2018, we expect to continue growing our SCS market share by demonstrating the clinical benefits of our Algovita system through clinical studies, obtaining MRI approvals, and building physician awareness of the benefits of the Algovita system. We also anticipate CE mark approval in the second quarter of 2018 of the Virtis sacral neuromodulation system (SNM), and are on track for FDA approval, with the expectation of a commercial launch in the United States in the second half of 2018.”

Click here to read the full press release.